# Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

Source: https://onco.cc/trials/nct06904235/  
OnCo record `nct06904235` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Palonosetron, Ondansetron and Aprepitant (and fosaprepitant) in childhood cancers, run by Helsinn Healthcare SA, now recruiting.

## Summary

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) is a phase 2 interventional study registered as NCT06904235 by Helsinn Healthcare SA, with 95 participants planned, started 2025-07-07 and due to reach its primary completion in 2027-10. Interventions recorded: IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion and Reference Treatment: IV fosaprepitant infusion.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06904235
- Phase: 2
- Setting: A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)
- Sponsor: Helsinn Healthcare SA
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT06904235: https://clinicaltrials.gov/study/NCT06904235

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- drugs: [Aprepitant (and fosaprepitant)](https://onco.cc/drugs/aprepitant/), [Ondansetron](https://onco.cc/drugs/ondansetron/), [Palonosetron](https://onco.cc/drugs/palonosetron/)
- companies: [Helsinn](https://onco.cc/companies/helsinn/)

---
JSON: https://onco.cc/api/v1/entities/nct06904235.json